仮想スクリーニングと細胞実験に基づくSGLT2阻害剤のスクリーニング
Dan Liu1, Lei Yu2,3, Mei Ling Cao1
1Inner Mongolia Medical University, Hohhot, People's Republic of China.
Scientific reports
|August 26, 2025
まとめ
研究者は,仮想スクリーニングと分子ドッキングを使用して,ナトリウム-グルコースコトランスポーター2 (SGLT2) を阻害する13の強力な化合物を特定しました. これらの化合物は,グルコースの吸収を減らすことで,糖尿病の新たな治療法として有望です.
科学分野:
- 薬剤化学
- コンピュータによる薬物発見
- 薬理学について
背景:
- 2型糖尿病 (T2DM) は,新しい治療戦略を必要とする世界的な健康問題です.
- SGLT2阻害剤は,抗糖尿病薬の主要なクラスである.
- 効能と特異性を改善した新しいSGLT2阻害剤の開発は極めて重要です.
研究 の 目的:
- 新しいヒット化合物をSGLT2阻害体として計算および実験的方法を使用して識別する.
- 特定された化合物のSGLT2に対する抑制力を評価する.
- SGLT2タンパク質との結合相互作用を調査する.
主な方法:
- 仮想スクリーニングと3次元製薬モデルが初期化合物選択に使用された.
- 定量的な構造-活動関係 (QSAR) モデリングが利用されました.
- バイオアッセイ (293T細胞におけるグルコース吸収) と分子ドッキングを検証と相互作用分析のために実施した.
主要な成果:
- 20の化合物は当初,潜在的な糖尿病治療として仮想スクリーニングで選択されました.
- 13のヒット化合物は強いSGLT2阻害特性を示し,化合物2は最も低いグルコース吸収を示した.
- 分子ドッキングで 安定した特定の水素結合相互作用が 確認されました
結論:
- 重要なSGLT2阻害作用を持つ13の新しい化合物が特定されました.
- これらの化合物は,糖尿病の管理のための新しい治療薬として潜在性を示しています.
- この研究は,薬剤発見のための計算と実験のアプローチの組み合わせを検証しています.
関連する概念動画
Glucose Transporters
24.1K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
24.1K
Secondary Active Transport
7.6K
One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme "pump" embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
7.6K
Glucose Absorption Into the Small Intestine
32.4K
Complex carbohydrates consumed cannot be absorbed into the small intestine in their original form. First, they must be hydrolyzed to a monosaccharide form such as glucose or galactose. These monosaccharides are then transported across the intestinal membrane and into the blood via transcellular transport. The intestinal epithelial cells allow the movement of these monosaccharides with a defined 'entry' through membrane transporter proteins present on their apical membrane and...
32.4K
Dipeptidyl Peptidase 4 Inhibitors
256
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
256
Methods for Studying Drug Absorption: In vitro
332
In vitro experiments are crucial for understanding the transport and absorption of drugs through biological materials. These studies employ varied methods such as the diffusion cell method, the everted sac technique, and the everted ring technique.
The diffusion cell method uses a two-compartment cell, including a donor compartment with the drug solution, which simulates the environment where the drug is applied, and a receptor compartment with a buffer solution, which simulates the environment...
The diffusion cell method uses a two-compartment cell, including a donor compartment with the drug solution, which simulates the environment where the drug is applied, and a receptor compartment with a buffer solution, which simulates the environment...
332
Glucagon-like Receptor Agonists
416
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
416


